Richard specialises in all aspects of contentious and non-contentious intellectual property law. He has handled a wide range of cases, transactions and advisory work for numerous clients in the fields of pharmaceuticals, chemicals, biotechnology and other disciplines.
Richard is experienced in patent, copyright and trade mark infringement cases and passing off actions. He has extensive experience of technology transfer and international licensing and advises on related competition law and regulatory matters. He also regularly assists corporate lawyers in the sale of shares and assets of companies and financings where intellectual property is involved.
- Recent Work
- advising the European Investment Bank on its first “at risk co-development funding” for the development of selected potential breakthrough medicines of UCB
- advising the syndicate of underwriting banks on the IP aspects of Circassia’s successful IPO, one of the biggest ever biotech fundraisings at IPO in the UK
- advising Genmab on various licensing arrangements, including on its $2.1bn collaboration agreement with GlaxoSmithKline relating to the exclusive codevelopment and commercialisation of Genmab's fully human monoclonal antibody, HuMax-CD20
- providing intellectual property advice to the Department for Innovation, Universities and Skills on the formation of the Energy Technologies Institute, a £1bn PPP involving some of the world's largest energy companies
- advising the Ministry of Defence on various substantial projects involving significant intellectual property issues
- advising various pharmaceutical, biotechnology, medical device and TMT companies in relation to partnering arrangements and licensing of technology.
Richard's commercial intellectual property (IP) practice and Life Sciences transactional work is specifically rated in The Legal 500 (where he is described as "superb") and Chambers (where he is described as "exceptionally smart" and puts clients at ease because "he really knows what he is talking about"). He is listed as an IP expert by Legal Business in Legal Experts Report. He is named in Euromoney's Guide to the World's Leading Patent Law Experts, Monday's world's leading IP lawyers survey, Who's Who in Life Sciences, Who’s Who Business Lawyers and Who’s Who Legal. He is also acknowledged and highly recommended in both PLC Cross-Border Intellectual Property and Life Sciences Handbooks. He has been nominated as one of the world’s leading IP strategists and was featured in IAM 250 – A Guide to the World’s Leading IP Strategists produced by Intellectual Asset Management (IAM) magazine. He has been acknowledged in IAM Licensing 250 - The World's Leading Patent and Technology Licensing Lawyers (where he is described as an "authority figure" and clients appreciate his "straightforward and extremely robust advice"). Listed as a leading individual in the London Super Lawyers Magazine (Thomson Reuters), Guide to the World’s Leading Patent Law Practitioners and Managing Intellectual Property’s IP Stars. In IAM Patent 1000, he is described as “a commercial patent lawyer who consistently comes up with the goods”.
Richard has written a substantial number of articles for legal and pharmaceutical journals and lectures extensively in the UK and elsewhere on intellectual property related matters. He is a former lecturer on "IP aspects of corporate transactions" for Bristol University's IP Diploma course workshop. Richard is the coauthor of Successful Licensing: Negotiating and Drafting Optimum Pharmaceutical Deals, published by FT Pharmaceuticals. He contributed to the intellectual property section of the book by W K Knight, The Acquisition of Private Companies and Business Assets (7th edition), published by FT Law & Tax. He also contributed a chapter to IP Client Strategies in Europe, published by Thomson Reuters/Aspatore (2010 Ed). He also co-authored a chapter in IP Issues in Corporate Transactions: A Practical Guide to the Treatment of Intellectual Property in Acquisitions and Investments published by Globe Law and Business (2015 Ed).
Richard obtained degrees in science and law before training as a solicitor with Simmons & Simmons. He qualified in 1988 and became a partner in 1996.
Richard is a member of the Healthcare Committee of the Licensing Executives Society and a member of the CBI IP Committee.